SCHEMBL25917491

SCHEMBL25917491

CCOC(=O)C(CC)CCCc1cccc2c1cnn2C1CCCCO1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.37
▸ RXRB P28702 1/20 0.37
▸ RXRG P48443 1/20 0.37
▸ ELANE P08246 1/20 0.34
▸ CYP4F2 P78329 3/20 0.33
▸ CYP4A11 Q02928 3/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ HTR2A P28223 5/20 0.32
▸ CYP3A4 P08684 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ CHRM2 P08172 1/20 0.32
▸ CHRM1 P11229 1/20 0.32
▸ DRD1 P21728 1/20 0.32
▸ SLC6A4 P31645 1/20 0.32
▸ OPRM1 P35372 1/20 0.32
▸ DRD3 P35462 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30724046 0.93 RXRA (0.35) RXRARXRBRXRGELANECYP4F2
SCHEMBL25918141 0.93 RXRA (0.35) RXRARXRBRXRGELANECYP4F2
SCHEMBL25917489 0.90 RXRA (0.40) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL25917431 0.85 CYP4F2 (0.43) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL25917465 0.84 RXRA (0.37) RXRARXRBRXRGELANECYP4F2
SCHEMBL25917448 0.83 ALDH1A1 (0.32) ELANECYP4F2CYP4A11MEN1ALDH1A1
SCHEMBL30724001 0.82 RXRA (0.39) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL25918142 0.82 RXRA (0.39) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL24179545 0.78 RXRA (0.46) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL25918087 0.77 MAPK8 (0.36) RXRARXRBRXRGCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242507-A1 INDAZOLE-FUSED CYCLIC COMPOUND Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) 2023-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242507-A1 INDAZOLE-FUSED CYCLIC COMPOUND SLC5A11, CYP11B2, CYP4F11 RXRA 3699/4885RXRB 3804/4885RXRG 3907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback